Skip to main content
SpringerLink
Log in

Heart Failure: From Epidemiology to Pathophysiology

  • Chapter
Thyroid and Heart Failure

  • 1037 Accesses

Abstract

Heart failure (HF) is the leading cause of hospitalization, giving rise to costs that outrun those of all other causes of disability, illness, and death throughout developed and even developing countries. HF is an enormous health problem, leading to significant morbidity and mortality. The pathogenetic interpretation of HF has radically changed in the last 40 years. Nowadays HF is considered a systemic disease that derives from a “faulty” neurohormonal response by the organism to primary cardiac damage that is able to elicit the activation of powerful, phylogenetically well-established mechanisms against the life-threatening loss of blood volume, such as hemorrhage, hypovolemia, and trauma. The degree of systemic activation is disproportionate to the severity of the primary cardiac damage, and it is this that is responsible for the development of HF and its progression. Early clinical recognition of neurohumoral activation is essential to prevent progression of HF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rosamond W, Flegal K, Friday G et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2007) Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115:e69–e171

    Article  PubMed  Google Scholar 

  2. Scholte op Reimer WJM, Gitt AK, Boersma E, Simoons ML (eds) (2006) Cardiovascular diseases in Europe. Euro Heart Survey. European Society of Cardiology, Sophia Antipolis, France

    Google Scholar 

  3. Roger VL, Weston SA, Redfield MM et al (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 292:344–350

    Article  PubMed  CAS  Google Scholar 

  4. Schocken DD, Benjamin EJ, Fonarow GC et al; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group, Functional Genomics and Translational Biology Interdisciplinary Working Group (2008) Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117:2544–2565

    Article  PubMed  Google Scholar 

  5. Lloyd-Jones DM, Larson MG, Leip EP et al; Framingham Heart Study (2002) Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106:3068–3072

    Article  PubMed  Google Scholar 

  6. Davis SK, Liu Y, Gibbons GH (2003) Disparities in trends of hospitalization for potentially preventable chronic conditions among African Americans during the 1990s: implications and benchmarks. Am J Public Health 93:447–445

    Article  PubMed  Google Scholar 

  7. Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20:248–254

    Article  PubMed  CAS  Google Scholar 

  8. Harris P (1988) Role of arterial pressure in the oedema of heart disease. Lancet 1:1036–1038

    Article  PubMed  CAS  Google Scholar 

  9. Schrier RW, Abraham WT (1999) Homones and hemodynamics in heart failure. N Engl J Med 341:577–585

    Article  PubMed  CAS  Google Scholar 

  10. Dauteman KW, Massie BM, Gheorgiade M (1998) Heart failure associated with preserved systolic function: a common and costly clinical entity. Am Heart J 135:S310–319

    Article  Google Scholar 

  11. Smith GL, Masoudi FA, Vaccarino V et al (2003) Out-comes in heart failure patients with preserved ejection fraction. J Am Coll Cardiol 41:1510–1518

    Article  PubMed  Google Scholar 

  12. Weber KT, Brilla CG (1991) Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 83:1849–1865

    PubMed  CAS  Google Scholar 

  13. Owens DK, Sanders GD, Heidenreich PA et al (2002) Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J 144:440–448

    Article  PubMed  Google Scholar 

  14. Bardy GH, Lee KL, Mark DB et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237

    Article  PubMed  CAS  Google Scholar 

  15. Cleland JG, Daubert JC, Erdmann E et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators (2005) The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure. N Engl J Med 352:1539–1549

    Article  PubMed  CAS  Google Scholar 

  16. Bristow MR, Saxon LA, Boehmer J et al; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150

    Article  PubMed  CAS  Google Scholar 

  17. Kannel WB, D’Agostino RB, Silbershatz H et al (1999) Profile for estimating risk of heart failure. Arch Intern Med 159:1197–1204

    Article  PubMed  CAS  Google Scholar 

  18. Gheorghiade M, Sopko G, De Luca L et al (2006) Navigating the crossroads of coronary heart disease and heart failure. Circulation 114:1202–1213

    Article  PubMed  Google Scholar 

  19. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G (2001) Heart failure in the general population of men: morbidity, risk factors and prognosis. J Intern Med 249:254–261

    Article  Google Scholar 

  20. Kenchaiah S, Narula J, Vasan RS (2004) Risk factors for heart failure. Med Clin North Am 88:1145–1172

    Article  PubMed  Google Scholar 

  21. Mckee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure. The Framingham study. N Engl J Med 285:1441–1446

    PubMed  CAS  Google Scholar 

  22. He J, Ogden LG, Bazzano LA et al (2001) Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 161:996–1002

    Article  PubMed  CAS  Google Scholar 

  23. Levy D, Larson MG, Vasan RS et al (1996) The progression from hypertension to congestive heart failure. JAMA 275:1557–1562

    Article  PubMed  CAS  Google Scholar 

  24. Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in cogestive heart failure: the Framingham study. Am J Cardiol 34:29–34

    Article  PubMed  CAS  Google Scholar 

  25. Kenchainah S, Evans JC, Levy D et al (2002) Obesity and risk of heart failure. N Engl J Med 347:305–313

    Article  Google Scholar 

  26. Chae CU, Albert CM, Glynn RJ et al (2003) Mild renal insufficiency and risk of congestive heart failure in men and women ≥70 years of age. Am J Cardiol 92:682–686

    Article  PubMed  Google Scholar 

  27. Fried LF, Shlipak MG, Crump C et al (2003) Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41:1364–1372

    Article  PubMed  Google Scholar 

  28. Horio T, Miyazato J, Kamide K et al (2003) Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens 16(Pt1):938–944

    Article  PubMed  CAS  Google Scholar 

  29. L’Abbate A, Sambuceti G, Neglia D (2002) Myocardial perfusion and coronary microcirculation: from pathophysiology to clinical application. J Nucl Cardiol 9:328–337

    Article  PubMed  Google Scholar 

  30. Sambuceti G, Marzullo P, Giorgetti A et al (1994) Global alteration in perfusion response to increasing oxygen consumption in patients with single-vessel coronary artery disease. Circulation 90:1696–1705

    PubMed  CAS  Google Scholar 

  31. Sambuceti G, Marzilli M, Mari A et al (2005) Coronary microcirculatory vasoconstriction is heterogeneously distributed in acutely ischemic myocardium. Am J Physiol Heart Circ Physiol 288:H2298–H2305

    Article  PubMed  CAS  Google Scholar 

  32. Hachamovitch R, Hayes SW, Friedman JD et al (2003) Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107:2900–2907

    Article  PubMed  Google Scholar 

  33. Shaw LJ, Berman DS, Maron DJ et al; COURAGE Investigators. (2008) Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117:1283–1291

    Article  PubMed  Google Scholar 

  34. Boden WE, O’Rourke RA, Teo KK et al; COURAGE Trial Research Group (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503–1516

    Article  PubMed  CAS  Google Scholar 

  35. Picano E, Landi P, Bolognese L et al on behalf of the EPIC Study Group (1993) Prognostic value of dipyridamole-echocardiography early after uncomplicated myocardial infarction: a large scale multicenter trial. Am J Med 11:608–618

    Article  Google Scholar 

  36. Hachamovitch R, Hayes SW, Friedman JD et al (2003) Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107:2900–2907

    Article  PubMed  Google Scholar 

  37. Neglia D, Parodi O, Gallopin M et al (1995) Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. Circulation 92:796–804

    PubMed  CAS  Google Scholar 

  38. Neglia D, Michelassi C, Trivieri MG et al (2002) Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 105:186–193

    Article  PubMed  Google Scholar 

  39. Schindler TH, Nitzsche EU, Schelbert HR et al (2005) Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events. J Am Coll Cardiol 45:1505–1512

    Article  PubMed  Google Scholar 

  40. Camici PG, Crea F (2007) Coronary microvascular dysfunction. N Engl J Med 356:830–840

    Article  PubMed  CAS  Google Scholar 

  41. Di Carli MF, Dorbala S, Hachamovitch R (2006) Integrated cardiac PET-CT for the diagnosis and management of CAD. J Nucl Cardiol 13:139–144

    Article  PubMed  Google Scholar 

  42. Klein I, Danzi S (2007) Thyroid disease and the heart. Circulation 116:1725–1735

    Article  PubMed  Google Scholar 

  43. Pingitore A, Landi P, Taddei MC et al (2005) Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 118:132–136

    Article  PubMed  CAS  Google Scholar 

  44. Lowes BD, Minobe W, Abraham WT et al (1997) Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 100:2315–2324

    Article  PubMed  CAS  Google Scholar 

  45. Davis PJ, Davis FB (2002) Nongenomic actions of thyroid hormone on the heart. Thyroid 12:459–466

    Article  PubMed  CAS  Google Scholar 

  46. Fish SA, Mandel SJ (2005) The blood in thyrotoxicosis. In: Bravermann L, Utiger R (eds) Werner and Ingbar’s The Thyroid. Lippincott Williams and Wilkins, Philadelphia, pp 595–598

    Google Scholar 

  47. Vargas F, Moreno JM, Rodríguez-Gómez I et al (2006) Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 154:197–212

    Article  PubMed  CAS  Google Scholar 

  48. Napoli R, Biondi B, Guardasole V et al (2001) Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation 104:3076–3080

    Article  PubMed  CAS  Google Scholar 

  49. Kuzman JA, Gerdes AM, Kobayashi S, Liang Q (2005) Thyroid hormone activates Akt and prevents serum starvation-induced cell death in neonatal rat cardiomyocytes. J Mol Cell Cardiol 39:841–844

    Article  PubMed  CAS  Google Scholar 

  50. Laragh JH, Sealey JE (2003) Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 16:407–415

    Article  PubMed  CAS  Google Scholar 

  51. Lewicki JA, Protter AA (1995) Physiological studies of the natriuretic peptide family. In: Laragh JH, Brenner BM (eds) Hypertension: pathophysiology, diagnosis and management. New York, Raven Press, pp 1029–1053

    Google Scholar 

  52. Klein I, Ojamaa K (2001) Thyroid hormone and the cardiovascular system. N Engl J Med 344:501–509

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Sant’Anna School of Advanced Studies of Pisa, Pisa, Italy

    Antonio L’Abbate MD

  2. C.N.R. Institute of Clinical Physiology, Pisa, Italy

    Antonio L’Abbate MD

Authors
  1. Antonio L’Abbate MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. C.N.R. Clinical Physiology Institute, S. Cataldo Research Campus, Pisa, Italy

    Giorgio Iervasi  & Alessandro Pingitore  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Italia

About this chapter

Cite this chapter

L’Abbate, A. (2009). Heart Failure: From Epidemiology to Pathophysiology. In: Iervasi, G., Pingitore, A. (eds) Thyroid and Heart Failure. Springer, Milano. https://doi.org/10.1007/978-88-470-1143-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1143-4_1

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1142-7

  • Online ISBN: 978-88-470-1143-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation